Viyash Scientific Limited
Viyash Scientific Limited operates in Pharmaceuticals, part of the Healthcare sector. It booked ₹946 cr of revenue in its latest quarter (Q1 FY27) and kept 7.0% of sales as profit.
“The Company is a leading integrated pharmaceutical company with a global footprint, operating in the domains of Animal Health (APIs and finished dosage formulations) and analytical services.”
“To be a leading integrated animal health company committed to quality veterinary solutions globally.”
“To deliver quality products competitively, while adhering to high standard of quality, governance & `9,997 Mn compliance.”
Healthier than 62% of companies in Healthcare, on all six measures of filed financials. Each measure is ranked against the 105–150 companies that reported it.
Measures financial condition, not whether to buy. Learn what this score means · How this is calculated
- RSI (14)
- 38
At close. Not part of the score.
How much profit it earns on the money it employs
How much it owes, and whether earnings cover the interest
Whether reported profit actually arrives as cash
Whether sales and profit have grown, and how steadily
What today's price implies, against our models or its peers
How much of the promoters' stake is pledged, and how much they hold · highest in its sector on what we could measure
What if I invest in VIYASH?
Set a growth rate and see what a monthly SIP would add up to. Your assumption, our arithmetic.
The slider starts at 12%, taken from this company's own revenue trend. That is history, not a forecast — this is your assumption, and the figure above is arithmetic on it. Returns are not steady year to year, and a real holding would not grow in a straight line. We do not publish price targets or predict returns.
P/E, ROE, ROCE and margins are annualised from the latest quarter; per-share and balance-sheet ratios use the most recent balance sheet on file · prices as of 2026-09-17.
An educational model from the company's own filings, every assumption shown — not investment advice or a price target. Prices can stay above or below any model for years.
| Revenue from Operations | ₹946 cr |
| Other Income | ₹8 cr |
| Total Income | ₹955 cr |
| Cost of Materials | ₹402 cr |
| Purchases of Stock-in-Trade | ₹65 cr |
| Inventory Change (±) | ₹-33 cr |
| Employee Benefit Expense | ₹163 cr |
| Finance Costs | ₹13 cr |
| Depreciation & Amortisation | ₹62 cr |
| Other Expenses | ₹171 cr |
| Total Expenses | ₹842 cr |
| Profit before Tax | ₹112 cr |
| Tax Expense | ₹33 cr |
| Net Profit | ₹79 cr |
| Net margin on total income | 8.3% |
| Metric | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|
| Revenue | 858 cr | 920 cr | 946 cr |
| Total income | 872 cr | 936 cr | 955 cr |
| Expenses | 758 cr | 811 cr | 842 cr |
| Profit before tax | 73 cr | 125 cr | 112 cr |
| Tax | 25 cr | 59 cr | 33 cr |
| Net profit (owners' share) | 38 cr | 52 cr | 66 cr |
| Net margin (owners' share, on revenue) | 4.5% | 5.7% | 7.0% |
| EPS (₹) | 0.89 | 1.20 | 1.51 |
| Company | Price | Market cap | P/E | ROE | Net margin | 1-yr return |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹1,867 | ₹4.48 L cr | 38.6 | 13.9% | 18.9% | — |
| Divi's Laboratories Limited | ₹9,323 | ₹2.47 L cr | 68.7 | 21.5% | 29.3% | — |
| Torrent Pharmaceuticals Limited | ₹4,875 | ₹1.65 L cr | 82.0 | 27.0% | 11.5% | — |
| Zydus Lifesciences Limited | ₹1,135 | ₹1.13 L cr | 30.4 | 13.9% | 11.7% | — |
| Cipla Limited | ₹1,376 | ₹1.11 L cr | 35.2 | 9.2% | 11.1% | — |
| Laurus Labs Limited | ₹1,948 | ₹1.05 L cr | 71.5 | 27.7% | 18.1% | — |
| Dr. Reddy's Laboratories Limited | ₹1,175 | ₹98,113 cr | 55.1 | 4.7% | 5.5% | — |
| Aurobindo Pharma Limited | ₹1,690 | ₹97,243 cr | 23.7 | 10.9% | 11.3% | — |
| Lupin Limited | ₹2,098 | ₹95,936 cr | 16.9 | 25.2% | 17.1% | — |
| Action | Detail | Ex-date |
|---|---|---|
| Dividend | ₹0.5 / share | 8 Sep 2021 |
| Dividend | ₹0.2 / share | 21 Aug 2019 |
| Dividend | ₹0.2 / share | 20 Nov 2017 |
| Stock split | Stock Split From Rs.10/- to Rs.2/- | 25 Feb 2016 |
A company cannot decide everything on its own. Things like a top executive’s pay, issuing new shares, or re-appointing a director have to be put to the people who own the company, and they vote — one vote per share. So whoever owns the most shares has the most say.
Every vote count above is taken from the result the company filed with the stock exchange, certified by an independent counter. To work out what would have happened without the promoters, we simply remove their votes and re-apply the same legal bar the proposal had to clear. Nothing here is an estimate or an opinion.
Most Indian companies are controlled by a family or group — the promoters. The exchange requires them to be listed by name, including members who own no shares at all, and requires the company to disclose any business it does with them.
Names and holdings from the company’s shareholding pattern filed with the exchange; transactions from the related-party note in its annual report. Every figure is as filed — these are legal, disclosed dealings, and what to make of them is your call.